Email
Comments
Print-FriendlyMedical News
Gilead's Hepatitis C Therapy Called Successful
March 14, 2011
In early-stage study results reported recently to investors, Gilead Sciences Inc. said its four-drug combination eliminated hepatitis C virus in patients. The trial examined the use of Gilead GS-9256 and GS-9190 with the standard drugs ribavirin and peginterferon. The researchers plan to present their findings at the annual meeting of the European Association for the Study of the Liver, which begins March 30 in Berlin.
Adapted from:
San Francisco Chronicle
03.09.2011; Kristen Hallam, Bloomberg News
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
No comments have been made.
|
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
 | |
|
|
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
